R&D/Clinical Trials

Tapping Microbiome Science for New Treatments and Answers to Drug Efficacy

October 26, 2020

Anthony Finbow, CEO of Eagle Genomics, talks to Pharm Exec about how adding microbiome-based evidence to disease modeling will enable the life sciences industry to understand the subtleties of how drugs interact with different human ‘host’ environments, unlocking new potential for stratified treatments.

Advancing the Science for Minds: Dr. Husseini Manji, J&J

October 23, 2020

Dr. Husseini Manji talks to Pharm Exec about his new role as J&J's Head of Science for Minds and how he hopes to foster new ways to treat dementia and serious mental disorders and provide holistic mental care.

Early Vaccine Authorization Raises Ethical & Logistical Challenges for Trial Sponsors

October 18, 2020

This week's much-anticipated meeting of FDA’s vaccine advisory committee will address critical issues related to the testing and approval of vaccines to prevent COVID-19 infection.

Moving Toward the Pharmaceutical Industry of the Future with Translational Medicine

October 15, 2020

Gabi Hanna, MD highlights the need for an effective therapy for acute pancreatitis.

COVID-19 Vaccine Concerns Prompt Clinical Trial Transparency

September 20, 2020

With all eyes on efforts to research and test potential vaccines and therapies to combat the coronavirus pandemic, fears about overly accelerated development programs has heightened demands for wider access to information on study protocols, statistical analysis plans, and early results.

Success Factors for Orphan Drug Development

August 04, 2020

When approached correctly, drug development in the rare disease space can be quite successful – especially when powerhouses across the industry join forces and leverage the power of data to help drive potential treatment options.

Pharmaceutical Executive

Central Focus: Targeting Unmet Need in CNS

July 09, 2020

Former physician and clinical researcher Antony Loebel, now president and CEO of Sunovion Pharmaceuticals, discusses his career-long mission to advance novel treatments for patients suffering from serious and underserved CNS disorders.

Global Regulatory Collaborations Aim to Speed Access to New Vaccines & Drugs

June 29, 2020

The need for treatments to combat the spread of COVID-19 is promoting greater cooperation among drug regulatory authorities around the world, with FDA officials communicating more frequently with their counterparts in Europe, Canada, Japan and other nations through established programs and agreements.